AKT1 and Myocardial fibrosis: Notably, the detrimental effects in USP38-TG mice were significantly prevented by Amlexanox, as evidenced by reduced HW, HW/BW, HW/TL and LW/BW ratio (Figure 10B), improved cardiac function (Figure 10C), alleviated hypertrophic degree (Figure 10D), ameliorated myocardial fibrosis (Figure 10E), and decreased the protein expression of TBK1/Akt-GSK3β/mTOR signaling pathway (Figure 10F) in Amlexanox treated-USP38-TG mice compared with USP38-TG DMSO mice.